Phathom schedules October 29 results. Jefferies sets USD 16 target for Phathom Pharmaceuticals stock

Published on 10/21/2026 at 07:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 74.27 million, up 88.00 percent year over year. Jefferies targets Phathom Pharmaceuticals stock at USD 16.

Clinical and financial milestones

Phathom Pharmaceuticals scheduled its third-quarter results webcast for October 29, 2026, at 8:00 a.m. EDT.
Second-quarter revenue reached USD 74.27 million, an 88.00 percent year-over-year increase.
Jefferies lowered its price target from USD 20.00 to USD 16.00 on October 14, 2026.

PHAT, US71722W1071, Illustration mit AI erstellt.

Phathom schedules third-quarter results for October 29, while Jefferies sets a USD 16 target for Phathom Pharmaceuticals stock. GlobeNewswire reported on October 19, 2026, that the company will host its third-quarter financial results webcast on October 29, 2026, at 8:00 a.m. EDT. Investing.com said on October 14, 2026, that Jefferies cut its target from USD 20.00 to USD 16.00 while retaining a Buy rating.

Three recent milestones

On October 8, 2026, Phathom announced three scientific presentations for the American College of Gastroenterology meeting, covering VOQUEZNA analyses in gastroesophageal reflux disease. On October 12, 2026, the company highlighted cost-effectiveness data and reported that vonoprazan was featured in 38 independent abstracts at the meeting, according to GlobeNewswire. The October 19, 2026 results announcement is the latest milestone.

What does the target mean?

The analyst action weighs against strong operating growth. Second-quarter revenue was USD 74.27 million, up 88.00 percent from the prior-year period, while diluted earnings per share were negative USD 0.21 in the second quarter of 2026. Investing.com also reported that full-year revenue guidance had been reduced to USD 310 million to USD 325 million from USD 320 million to USD 345 million because of prescribing and prior-authorization challenges.

Next date for investors

The next substantiated company date is October 29, 2026, when management plans to discuss third-quarter results and provide a business update. The webcast is scheduled for 8:00 a.m. EDT, according to GlobeNewswire. The event should add a fresh operating checkpoint after the second-quarter revenue increase and the revised full-year range.

Commercial execution remains central

Phathom markets VOQUEZNA in the United States for several gastrointestinal indications and is advancing additional uses of vonoprazan. The October 12 data release included a retrospective analysis of 1,304 VOQUEZNA initiators and 1,304,683 prescription proton-pump-inhibitor initiators, giving the commercial story a broader real-world evidence base. The October 29 update will connect that evidence with reported revenue and guidance.